CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

thromboprofylaxis protocolWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug3011 standard protocol Wiki 1.00

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D013923 Thromboembolism NIH 0.27

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0001907 Thromboembolism HPO 0.24

There is one clinical trial.

Clinical Trials

1 Impact of Implementation of an Intensified Thromboprofylaxis Protocol in in Critically Ill ICU Patients With COVID-19: a Longitudinal Controlled Before-after Study

The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.

NCT04394000 COVID19 Thromboembolism Other: thromboprofylaxis protocol Other: standard protocol
MeSH:Thromboembolism
HPO:Thromboembolism

Primary Outcomes

Description: mortality was assessed in all COVID 19 patients admitted to the ICU

Measure: 2 week mortality

Time: 2 weeks after admission at ICU

Secondary Outcomes

Description: the incidence of venous thromboembolism was evaluated in all COVID 19 patients admitted to the ICU

Measure: incidence of venous thromboembolism

Time: during ICU stay up till 3th of May 2020

Description: mortality was assessed in all COVID 19 patients admitted to the ICU

Measure: 1 week mortality

Time: 1 week after admission at ICU

Description: mortality was assessed in all COVID 19 patients admitted to the ICU

Measure: 3 week mortality

Time: 3 weeks after admission at ICU

Description: mortality was assessed in all COVID 19 patients admitted to the ICU

Measure: 1 month mortality

Time: 1 month after admission at ICU

Description: incidence of acute kidney failure in all COVID 19 patients admitted to the ICU

Measure: incidence of kidney failure

Time: during ICU stay up till 3th of May 2020

Description: incidence of continuous renal replacement therapy (CRRT) in all COVID 19 patients admitted to the ICU

Measure: incidence of continuous renal replacement therapy (CRRT)

Time: during ICU stay up till 3th of May 2020

Description: evaluation of the lowest P/F ratio in all COVID 19 patients admitted to the ICU

Measure: lowest PaO2/FiO2 (P/F) ratio

Time: during ICU stay up till 3th of May 2020

Description: evaluation of the highest SOFA score in all COVID 19 patients admitted to the ICU

Measure: highest Sequential Organ Failure Assessment (SOFA) score

Time: during ICU stay up till 3th of May 2020

Description: evaluation of the length of stay in ICU and hospital of all COVID 19 patients admitted to the ICU

Measure: length of stay

Time: during ICU and hospital stay up till 3th of May 2020

Description: evaluation of the highest bilirubine level in all COVID 19 patients admitted to the ICU

Measure: highest bilirubin

Time: during ICU stay up till 3th of May 2020

Description: evaluation of the highest AST level in all COVID 19 patients admitted to the ICU

Measure: highest ( AST

Time: during ICU stay up till 3th of May 2020

Description: evaluation of the highest ALT level in all COVID 19 patients admitted to the ICU

Measure: highest Aspartaat-Amino-Transferase (ALT)

Time: during ICU stay up till 3th of May 2020

Related HPO nodes (Using clinical trials)

HP:0001907: Thromboembolism
Genes 27
HABP2 INHBA KCNN4 CYTB KIF20A MTRR CBS F2 FCGR2C SERPINC1 TNNT2 MTHFR KCNQ1 SLC4A1 PRDX1 TNNI3 MYPN ADA2 MMACHC PRKAR1A FLNC F13A1 PIEZO1 JAK2 PIGA EPOR HRG
Protein Mutations 3
G20210A G21210A R506Q
SNP 7
rs10276036 rs1128503 rs1202167 rs1202168 rs1202169 rs2235046 rs4148738